Presentation to take place on June 1 from 10:30 a.m. to
12:00 p.m. EDT at the Yale School of Management
NEW
HAVEN, Conn., May 9, 2023
/PRNewswire/ -- Trevi Therapeutics, Inc. (Nasdaq: TRVI),
a clinical-stage biopharmaceutical company developing the
investigational therapy Haduvio™ (oral nalbuphine ER) for difficult
to treat patients with chronic cough in idiopathic pulmonary
fibrosis (IPF), other chronic cough indications, and prurigo
nodularis, today announced its participation at the upcoming Yale
Innovation Summit taking place from May
31 – June 1 at the Yale School
of Management. The Company will present on its differentiated
central and peripheral mechanism in cough and the potential broad
translatability across cough indications.
![Trevi Therapeutics, Inc. www.trevitherapeutics.com (PRNewsfoto/Trevi Therapeutics, Inc.) Trevi Therapeutics, Inc. www.trevitherapeutics.com (PRNewsfoto/Trevi Therapeutics, Inc.)](https://mma.prnewswire.com/media/1504281/Trevi_Therapeutics_Logo.jpg)
Trevi's executives will be joined by one of the thought leaders
in cough, Peter Dicpinigaitis, MD.
Dr. Dicpinigaitis is a Professor of Medicine, Albert Einstein
College of Medicine, Division of Critical Care Medicine,
Montefiore Medical Center, Director, Montefiore Cough Center and
Editor-in-Chief, LUNG. Dr. Dicpinigaitis will discuss the various
central and peripheral pathways in cough and why a centrally active
mechanism is generating such interest. Trevi will also share
insights on the patient and commercial potential of Haduvio with
additional details from its physician and payer market research
across chronic cough indications. There will be a Q&A session
at the end of the presentation.
For more information about the conference and to attend the
presentation, please use the following link:
https://ventures.yale.edu/community/yale-innovation-summit
Conference Details
Yale Innovation Summit (May
31-June 1)
Presenters: Jennifer
Good, President and CEO of Trevi Therapeutics,
Farrell Simon, Chief Commercial Officer
of Trevi Therapeutics, and Peter Dicpinigaitis, MD,
Professor of Medicine, Albert Einstein College of
Medicine, Division of Critical Care
Medicine, Montefiore Medical Center,
Director, Montefiore Cough Center and Editor-in-Chief,
LUNG
Presentation: Thursday, June 1, 10:30
AM-12 PM ET
Registration: Investors and analysts can register to attend
the in-person event by using the following
link: https://ventures.yale.edu/yale-innovation-summit
A recording of the webcast will be available in the 'Investors
& News' section on the Company's website at
www.TreviTherapeutics.com.
The Company also plans to participate in the following upcoming
conferences and events:
- May 19-20: American Thoracic
Society's (ATS) 2023 Respiratory Innovation Summit
- May 19-24: ATS 2023 International Conference
- June 5-8: 2023 BIO International
Convention
- June 9-10: 2023 American Cough
Conference
About Trevi Therapeutics, Inc.
Trevi
Therapeutics, Inc. is a clinical-stage biopharmaceutical
company developing the investigational therapy
Haduvio™ (oral nalbuphine ER) for difficult to
treat patients with chronic cough in idiopathic pulmonary fibrosis
(IPF), other chronic cough indications, and
prurigo nodularis. Haduvio is a dual
ĸ-opioid receptor agonist and µ-opioid
receptor antagonist that works both centrally as well as
peripherally in the lungs and has the potential for a
synergistic anti-tussive effect to treat chronic
cough.
The impact of chronic cough is significant and often leads to a
decline in patients' social, physical, and psychological quality of
life. There are no approved therapies for the treatment of chronic
cough in IPF and current treatment options provide minimal relief
to patients. In IPF, chronic cough may lead to worsening fibrosis
and may be associated with a higher risk of progression, death, or
need for lung transplant.
Parenteral nalbuphine is not scheduled by the US DEA. Trevi
intends to propose Haduvio as the trade name for nalbuphine ER. Its
safety and efficacy have not been evaluated by any regulatory
authority.
For more information, visit www.TreviTherapeutics.com and
follow the Company on Twitter and LinkedIn.
Forward-Looking Statements
Statements contained in this press release regarding matters that
are not historical facts are "forward-looking statements" within
the meaning of the Private Securities Litigation Reform Act of
1995. Such statements are subject to risks and uncertainties and
actual results may differ materially from those expressed or
implied by such forward-looking statements. Such statements
include, but are not limited to, statements regarding Trevi's
business plans and objectives, including future plans or
expectations for Haduvio and plans and timing with respect to
future clinical trials, expectations regarding Trevi's uses and
sufficiency of capital, and other statements containing the words
"believes," "anticipates," "plans," "expects," and similar
expressions. Risks that contribute to the uncertain nature of the
forward-looking statements include: uncertainties regarding the
success, cost and timing of Trevi's product candidate development
activities and ongoing and planned clinical trials; the risk that
positive data from a clinical trial may not necessarily be
predictive of the results of future clinical trials in the same or
a different indication; uncertainties regarding Trevi's ability to
execute on its strategy; uncertainties with respect to regulatory
authorities' views as to the data from Trevi's clinical trials and
next steps in the development path for Trevi's Haduvio in
the United States and foreign
countries, including the Company's ability to submit and get
clearance on an IND on a timely basis; uncertainties inherent in
estimating Trevi's cash runway, future expenses and other financial
results, including Trevi's ability to fund future operations,
including clinical trials; uncertainties regarding the scope,
timing and severity of the COVID-19 pandemic, the impact of the
COVID-19 pandemic on Trevi's clinical operations and actions taken
in response to the pandemic; as well as other risks and
uncertainties set forth in the quarterly report on Form 10-Q for
the quarter ended March 31, 2023
filed with the Securities and Exchange Commission and in subsequent
filings with the Securities and Exchange Commission. All
forward-looking statements contained in this press release speak
only as of the date on which they were made. Trevi undertakes no
obligation to update such statements to reflect events that occur
or circumstances that exist after the date on which they were
made.
Investor Contact
Katie McManus
Trevi Therapeutics,
Inc.
203-304-2499
k.mcmanus@trevitherapeutics.com
Media Contact
Rosalia
Scampoli
914-815-1465
rscampoli@marketcompr.com
View original content to download
multimedia:https://www.prnewswire.com/news-releases/trevi-therapeutics-to-present-at-upcoming-yale-innovation-summit-2023-301819270.html
SOURCE Trevi Therapeutics, Inc.